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This study was carried out to examine the possible role of interleukin-1 (IL-1) in the functional insufficiency of regulatory T cells
in psoriasis, by comparing the expression of IL-1 receptors on healthy control and psoriatic T cells. Patients with moderate-to-
severe chronic plaque psoriasis and healthy volunteers, matched in age and sex, were selected for all experiments. CD4+CD25−
effector and CD4+CD25+CD127low regulatory T cells were separated and used for the experiments. Expression of the mRNA of IL-1
receptors (IL-1R1, IL-1R2, and sIL-1R2) was determined by quantitative real-time RT-PCR. Cell surface IL-1 receptor expression was
assessed by flow cytometry. Relative expression of the signal transmitting IL-1 receptor type 1 (IL-1R1) mRNA is higher in resting
psoriatic effector and regulatory T cells, and activation induces higher IL-1R1 protein expression in psoriatic T cells than in healthy
cells. Psoriatic regulatory and effector T cells express increased mRNA levels of the decoy IL-1 receptors (IL-1R2 and sIL-1R2) upon
activation compared to healthy counterparts. Psoriatic T cells release slightly more sIL-1R2 into their surrounding than healthy T
cells. In conclusion, changes in the expression of IL-1 receptors in psoriatic regulatory and effector T cells could contribute to the
pathogenesis of psoriasis.
1. Introduction
Psoriasis, a common inflammatory skin disorder affecting 1-
2% of individuals in Western societies, is caused by genetic
predisposition and can be triggered or affected by various
environmental provoking factors, such as mechanical stress
(Koebner phenomenon), infections, emotional stress, diet,
body mass index, alcohol consumption, smoking, certain
drugs, and climatic effects [1–3]. Psoriatic skin lesions are
infiltratedwith activatedT cells andhyperstimulatory antigen
presenting cells [4–6]. Recently published studies suggest
that intralesional activated T cells produce cytokines that
trigger primed basal stem cell keratinocytes to proliferate
and perpetuate skin inflammation. The interaction between
keratinocytes and immune cells via autocrine and paracrine
network of cytokines is a key component in the development
of psoriasis [7, 8].
Interleukin-1 (IL-1) is a potent inflammatory cytokine
implicated in host-defence responses to injury and infection.
Several factors (IL-1 receptors, agonists, and antagonists)
are involved in the regulation of IL-1 activity [9]. The type
1 receptor (IL-1R1) is described as a signal transmitting
receptor, triggered by both IL-1𝛼 and IL-1𝛽 ligands. The
intracellular domain of IL-1R1 is responsible for initialising
the inflammatory signalling processes in target cells.The type
2 IL-1 receptors (IL-1R2) are decoy receptors, as they are
lacking the intracellular signal transmitting domain for
mediating the IL-1 effect. IL-1R2 can be found associated
with the plasma membrane and in soluble, secreted forms.
Both of these receptor forms strongly bind IL-1; however,
they are unable to initialise the IL-1 signalling pathway.
Soluble IL-1R2 protein is produced by shedding from the cell
surface or synthesised in a soluble form from a distinct gene
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(sIL-1R2). The contribution of IL-1 and related signalling to
inflammatory skin diseases and to psoriasis pathogenesis is
supported by several studies [10, 11].
According to our recently published data, psoriatic
CD4+CD25+ regulatory T cells (Treg) are functionally defec-
tive in suppressing activated CD4+CD25− effector T cell
(Teff) proliferation compared to healthy Treg cells [12].
However, the reasons for regulatory T cell deficiency remain
mostly unknown. Since IL-1 signalling leads to the release
of several proinflammatory cytokines, including TNF𝛼, IL-
17A [13], and IL-6, it has been implicated in preventing
immune suppression by regulatory T cells [14]. Therefore,
we hypothesised that the IL-1 signalling pathway may be
involved in the functional deficiency of regulatory T cells in
psoriasis. This study aims to compare the expression of IL-
1 receptor isoforms in Treg and Teff cells from psoriatic and
healthy individuals.
2. Materials and Methods
2.1. Patients. Patients with moderate-to-severe chronic
plaque type psoriasis and healthy volunteers, matched in
age and sex, were selected for all experiments. Psoriatic
patients were either untreated or had only received topical
therapy during the last 4 weeks before sampling. Samples
were collected from at least four patients and four healthy
volunteers for each experiment. The study was approved by
the Human Investigation Review Board of the University
of Szeged, compiling with the ethical standards of research
and in accordance with the Helsinki Declaration. Written
informed consent was obtained from all donors involved in
the study.
2.2. Reagents. Human T Regulatory Lymphocyte Isolation
Set, anti-CD127-PE, anti-CD45RO-FITC, anti-CD25-APC,
PE and APC conjugated streptavidin, and human recom-
binant IL-2 protein were purchased from BD Biosciences
(San Jose, CA, USA). All flow cytometry and flow sorting
experiments were done on FACSCalibur flow cytometer
and data were analysed with CellQuest software (BD Bio-
sciences). RPMI-1640medium, anti-CD3/CD28 coated bead,
and TRIzol reagent were from Life Technologies (Carls-
bad, CA, USA). Foetal bovine serum (FBS) was obtained
from HyClone Laboratories, Inc. (South Logan, Utah, USA).
Anti-CD4-PerCP, biotinylated anti-IL-1R1, anti-IL-1R2, and
Human sIL-1R2 Quantikine ELISA Kit were from R&D
Systems (Minneapolis, MN, USA), and anti-GARP-PE
(LRRC32) was from ENZO Life Sciences (Farmingdale, NY,
USA). Antibiotic/Antimycotic Solution, L-glutamine,MEM’s
Vitamin Solution, and sodium-azide were purchased from
Sigma-Aldrich (Saint Louis, MO, USA). Ficoll Paque was
acquired fromGEHealthcare Biosciences (Uppsala, Sweden).
2.3. Isolation and Activation of Regulatory and Effector T Cells.
After gradient centrifugation of peripheral blood from psori-
atic patients and healthy volunteers using Ficoll Paque, CD4+
cells were separated from peripheral blood mononuclear
cells by negative selection using antibody-coupled magnetic
beads. Activation of the cells was carried out by incubation
with CD3/CD28 beads (1 : 4 bead to cell ratio) for 1, 6, and 24
hours (RT-PCR experiments), 48 hours (for flow cytometry),
and 72 hours (ELISA experiments), following the instructions
of the manufacturer.
Different T cell subpopulations were identified by flow
cytometer using CD45RO and CD25 labelling. CD45RO and
CD25 double negative cells were considered as naı¨ve T cells
(TN), CD45RO negative and CD25 positive cells as naı¨ve
regulatory T cells (TNreg), CD45RO positive and CD25
negative cells as memory T cells (TM), and CD45RO and
CD25 double positive cells as regulatory T cells (Treg); in the
case of activated cells anti-GARP antibody was used instead
of anti-CD25 for discriminating CD4+ subpopulations, as
previously described [15].
CD4+ and CD4+CD25+ cells were separated with Human
T Regulatory Lymphocyte Isolation Set for real-time RT-PCR
and ELISA experiments. CD127low cells were further selected
from the CD4+CD25+ population by anti-CD127 antibodies
and flow cytometer assisted sorting as described previously
[16].
2.4. Cell Culture. T cells were maintained in RPMI-1640
medium supplementedwith 10% FBS, 1%Antibiotic/Antimy-
cotic Solution, 1% L-glutamine, andMEM’s Vitamin Solution
at 37∘C in a humidified atmosphere containing 5% CO
2
.
2.5. Real-Time RT-PCR. Regulatory and effector T cells were
activated at indicated times and total RNA was isolated
using TRIzol reagent; RNA concentration was determined by
A260 values. cDNA was synthesised from 1 𝜇g of total RNA
using the Bio-Rad iScript cDNA Synthesis Kit, and RT-PCR
experiments were done on the iCycler IQ Real-Time PCR
machine of Bio-Rad (Hercules, CA, USA). The abundance of
each gene of interest was normalised to the expression of 18S
ribosomal rRNA gene from each examined sample; data are
expressed as an arbitrary number proportional to the mRNA
level.
2.6. Flow Cytometry. CD4+ T cells were cultured overnight
after the separating procedure. Activated cells were incubated
for two days with CD3/CD28 coated beads in the presence
of 10U/mL IL-2. Control cells were incubated without beads
and IL-2.After twodays cellswere harvested andwashed once
with PBS. CD4+ cells were >95% pure as verified by anti-
human CD4-PerCP labelling. Different cell populations were
identified by staining with anti-human CD45RO-FITC and
anti-humanCD25-APC or anti-humanGARP-PE 45minutes
on ice. Cells were labelled with biotinylated anti-human IL-
1R1 or biotinylated anti-human IL-1R2 monoclonal antibod-
ies or appropriate isotype controls in 1 𝜇g/mL concentration
for 45 minutes on ice. After washing two times with FACS
buffer (1% FBS + 0.1% sodium-azide in PBS) PE- or APC-
conjugated streptavidin was added and incubated for 30min-
utes on ice. Samples were washed and resuspended in 500𝜇L
FACS buffer; staining was measured using FACSCalibur.
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2.7. Determination of Secreted sIL-1R2 by Using ELISA Tech-
nique. Hundred-thousand normal and psoriatic effector and
regulatory T cells were grown per wells in a ninety-six well
plate. Supernatants of control and CD3/CD28 activated cells
were harvested after three days of incubation. Soluble IL-1R2
protein level in the supernatants was determined by using
an ELISA Kit for sIL-1R2 following the instructions of the
manufacturer.
2.8. Statistical Analysis. All data were statistically analysed
and compared for significance using one-way ANOVA
(Holm-Sidakmethod) formultiple comparisons in SigmaPlot
software (Systat Software, Inc., Chicago, IL, USA).
3. Results
3.1. Psoriatic Naı¨ve,Memory, Naı¨ve Treg, andTreg Cell Popula-
tions Are Quantitatively Identical to Healthy Cell Populations.
CD4+ T cells were isolated from PBMC fractions of healthy
and psoriatic peripheral blood samples using magnetic bead
technique. Na¨ıve (TN), memory (TM), naı¨ve regulatory
(TNreg), and regulatory T cell (Treg) subpopulations were
identified by CD45RO and CD25/GARP labelling (Figures
1(a) and 1(b)). Similar distribution of T cell populations was
found in resting normal and psoriatic samples and there was
no significant difference in the cell number of control and
psoriatic T cell subgroups. About 40% na¨ıve, 45% memory,
and 2–5% TNreg and Treg were detected among CD4+ cells
(Figure 1(c)) and no significant changes were observed two
days after CD3/CD28 stimulation.
3.2. Psoriatic Treg Cells Display a Consistently Increased IL-
1R1 Gene Expression Compared to Healthy Counterparts. In
order to investigate the IL-1R1 mRNA expression in CD4+
T cell subpopulations, peripheral blood mononuclear cells
were separated into CD4+CD25− effector cells (Teff) and
CD4+CD25+CD127− regulatory cells (Treg) using a combi-
nation of magnetic bead and flow cytometer assisted sorting
method (Figure 2(a)). Total RNA was isolated from control
and CD3/CD28 bead activated cells, and IL-1R1 mRNA level
was detected by real-time RT-PCR (Figure 2(b)). Control
resting Teff cells expressed very low levels of IL-1R1 mRNA
both in healthy and psoriatic samples. Activation significantly
induced IL-1R1 gene expression in Teff cells; the induction
was more pronounced in psoriatic Teff cells at all time points
examined, although the differences between healthy and
psoriatic samples were not statistically significant.
Resting Treg cells showed higher IL-1R1 gene expression
compared to Teff cells, with the psoriatic Treg cells showing
elevated mRNA levels over healthy counterparts. IL-1R1
mRNA expression was consistently induced in healthy Treg
cells reaching the highest level at 6 hours and remaining
elevated at 24 hours after CD3/CD28 stimulation (statisti-
cal significance at 24 hours, Figure 2(b)). Psoriatic T cells,
however, did not respond with further increase of IL-1R1
mRNA levels to T cell receptor activation signals; even a slight
decrease was observed at 24 hours. IL-1R1 gene expression
was still higher in activated psoriatic Treg cells compared
to healthy counterparts (statistical significance at 24 hours,
Figure 2(b)).
3.3. The Induction of IL-1R2 and sIL-1R2 Gene Expressions
following Cell Activation Is More Prominent in Psoriatic Teff
Cells Compared to Healthy Ones. ThemRNA expression pat-
tern of the two decoy IL-1 receptors (IL-1R2 and sIL-1R2) was
strikingly similar. There was no significant difference in the
baseline mRNA expression of the IL-1R2 (Figure 2(c)) and
sIL-1R2 (Figure 2(d)) genes between healthy and psoriatic
Teff or Treg cells. Upon CD3/CD28 activation, the mRNA
expression of the decoy IL-1 receptors increased in every
Teff and Treg samples examined (statistically significant
differences at 24 hours after activation in psoriatic Teff IL-
1R2mRNA expression; and in both healthy and psoriatic Treg
IL-1R2 and sIL-1R2 mRNA expression compared to baseline
resting cells). After T cell receptor stimulation psoriatic T
cells expressed higher levels of the decoy IL-1 receptors
than healthy counterparts (significant differences between
psoriatic and healthy Teff cells in IL-1R2 and sIL-1R2 mRNA
expressions at 24 and 6 hours after activation, resp.).
3.4. Higher Percentage of Activated Psoriatic Treg Cells
Expresses IL-1R1 Protein with Decreased Intensity Compared
to Healthy Cells. Normal and psoriatic CD4+ cells were
cultured for two days in the presence (activated cells) or
absence (control cells) of anti-CD3/CD28 coated beads and
IL-2 (10U/mL). Cell surface IL1R1 and IL-1R2 expressions
were determined using flow cytometry. T cell subpopula-
tions (TN, TM, TNreg, and Treg) were gated as previously
described (Figure 1(a)). Percentage of cells showing IL-1R1
positivity was compared between control healthy and pso-
riatic samples (Figure 3(a)). In resting T cells, IL-1R1 is
expressed at the highest percentage in the Treg subpopulation
both in healthy and psoriatic samples, reaching 32.31% and
31.87%, respectively. Cell surface presence of IL-1R1 was
notably lower in TM (17.89%/19.52%) and TN (16.21%/11.73%)
subpopulations. The intensity of IL-1R1 receptor expression
(Figure 3(c)) was higher in psoriatic Treg cells (mean flu-
orescent intensity, MFI = 34.26) compared to healthy
counterparts (MFI = 24.84); however this difference was not
significant (𝑃 = 0.117).
Upon activation, the number of IL-1R1 expressing cells
displayed a vast increase, with amore pronounced rise in pso-
riatic Treg cells, resulting in a significant difference between
the number of IL-1R1 positive cells in the healthy (68.4%)
and psoriatic (80.8%) samples (Figure 3(a)). We detected a
notable increase in IL-1R1 expression intensity (Figure 3(c))
two days after CD3/CD28 stimulation in healthy Treg cells
(MFI = 54.11); this was not observed in psoriatic samples
(MFI = 35.7).
The ratio of the IL-1R1 positive cells in the TM sub-
population increased to 48.39% in healthy and 47.8% in
psoriatic samples two days after activation (Figure 3(a)).
CD3/CD28 stimulated healthy TM cells presented a signifi-
cant increase in the intensity of IL-1R1 staining (Figure 3(c),
control MFI = 23.32, activated MFI = 45.83), whereas
psoriatic TM cells displayed no change compared to resting
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Figure 1: Distribution of CD4+ T lymphocyte subpopulations is not different in healthy and psoriatic peripheral blood samples. CD4+ T
cells were isolated from healthy and psoriatic donors and were activated for two days with CD3/CD28 beads in presence of IL-2; control cells
were incubated without any treatment. Cells were stained with anti-CD45RO-FITC and anti-CD25-APC to identify T cell subpopulations
such as naı¨ve T (TN, CD45RO−CD25−), memory T (TM, CD45RO+CD25−), na¨ıve regulatory T (TNreg, CD45RO−CD25+), and regulatory T
cells (Treg, CD45RO+CD25+) (a). Anti-GARP-PE antibody was used instead of anti-CD25 to differentiate activated cells (b). Representative
scatterplots from healthy samples are shown. Percentage of cells in each population was determined and shown as the mean of four
independent samples from healthy (H) and psoriatic (P) peripheral blood (c). Control resting cells and activated cells are represented by
black and white bars, respectively.
cells (control MFI = 31.71, activated MFI = 35.86). No
significant changes were detected in the number of IL-
1R1 expressing TN cells following activation; however the
expression intensity of the protein was increased in healthy
TN as well. Taken together, these results demonstrate that
activation induces IL-1R1 receptor expression on the surface
of both healthy and psoriatic Treg and TM cells; however,
receptor density is only increasing in healthy T cells upon
CD3/CD28 activation.
3.5. IL-1R2 Expressing Treg and TMCells Are Greatly Increased
upon Activation. CD4+ cells were treated and labelled as
previously described for flow cytometry analysis of healthy
and psoriatic samples (Figure 1(a)).TheT cell subpopulations
Mediators of Inflammation 5
Treg
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD25
CD
1
2
7
Treg sort gate settings
(a)
10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
10
10
IL-1R1
#, &
#, &
∗
#
m
RN
A
 ex
pr
es
sio
n
Control 1h 6h 24h Control 1h 6h 24h
Treg Teff
(b)
Healthy
Psoriatic
#, &
&
∗
10
0
10
1
10
2
10
3
10
4
10
5
m
RN
A
 ex
pr
es
sio
n
IL-1R2
Control 1h 6h 24h Control 1h 6h 24h
Treg Teff
(c)
Healthy
Psoriatic
#, &
∗
10
0
10
1
10
2
10
3
10
4
10
5
m
RN
A
 ex
pr
es
sio
n
sIL-1R2
Control 1h 6h 24h Control 1h 6h 24h
Treg Teff
(d)
Figure 2: IL-1 receptor mRNA expression is different in psoriatic T cells compared to healthy counterparts. Healthy and psoriatic effector
(Teff) and regulatory (Treg) T cells were separated from PBMC fractions. Teff cells were isolated via negative selection method by magnetic
beads. Treg cells were sorted from CD4+CD25+ population using anti-CD127 labelling; sorting gate was set for CD25highCD127low cells
(a). Isolated Treg and Teff cells were activated with anti-CD3/CD28 coated beads for indicated times and mRNA expression changes of
IL-1 receptor isoforms were determined by real-time RT-PCR at 0 h baseline control and 1 h, 6 h, and 24 h after CD3/CD28 stimulation.
Comparison of the expression of IL-1R1 (b), IL-1R2 (c), and sIL-1R2 (d) genes in T cells from healthy (𝑛 = 3, black circles) and psoriatic
samples (𝑛 = 4, white circles); mean values are indicated by solid and dashed lines, respectively. Gene expression values are represented as
arbitrary numbers normalised to the expression of 18S rRNA gene. ∗—significant difference (𝑃 < 0.05) between healthy and psoriatic samples
and significant difference (𝑃 < 0.05) between baseline and activated mRNA levels of healthy (#) and psoriatic (&) samples.
were defined and IL-1R2 expression was determined. Most of
the resting cells from all CD4+ subpopulations studied were
negative for the IL-1R2 decoy receptor (Figure 3(b)). Unlike
the IL-1R1 protein, the membrane bound decoy receptor
was not expressed in a higher percentage among Treg cells.
However, two days after activation most Treg cells displayed
IL-1R2 positivity. Only a moderate increase was observed in
IL-1R2 expressing TM and almost no change in TN sub-
populations. Intensity of cell surface IL-1R2 expression
(Figure 3(d)) was increased in healthy Treg and TM cells
uponCD3/CD28 stimulation, whereas in the case of psoriatic
samples we noticed a minor decrease in IL-1R2 expression
intensity; these changes were not statistically significant.
3.6. Slightly Elevated sIL-1R2 Production in Psoriatic T Cells
Compared to Healthy T Cells. After determining the cell sur-
face decoy IL-1 receptor expression, we examined whether
Treg and Teff cells from control and psoriatic individuals
released soluble IL-1R2 into the supernatant upon activa-
tion. The concentration of IL-1R2 in the supernatant of the
cells was determined by ELISA in resting state and after
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Figure 3: Expression of IL-1R1 and IL-1R2 proteins in healthy control and psoriatic CD4+ cells. Healthy and psoriatic CD4+ cells were isolated
and labelled as described. Cell surface IL-1R1 (a) and IL-1R2 (b) proteins were stained with biotinylated primary antibodies and PE/APC-
conjugated streptavidin. Percentage of positive cells of CD4+ Treg, TM, and TN subpopulations from individual samples is depicted (𝑛 = 4).
Circles represent resting cells (CON), whereas CD3/CD28 stimulated cells (ACT) are indicated as triangles. Mean fluorescence intensities
(MFI) of IL-1R1 (c) and IL-1R2 (d) positive cells are shown. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
three days of CD3/CD28 activation. We detected a notable
release of IL-1R2 protein, especially following activation.
Although Teff cells secreted higher amounts of the protein
into the supernatant than Treg cells, the differences were
not statistically significant either in healthy or in psoriatic
cells (Figure 4). Psoriatic T cells produced slightly but not
significantly higher levels of the sIL-1R2 protein compared to
healthy counterparts.
4. Discussion
Psoriasis is an inflammatory skin disease, with complex dys-
regulation of cutaneous immunity [17]. Psoriatic plaque
formation is initiated by components of the skin innate
immune system and sustained by the abnormal interaction
of skin resident cells with cells of the hematopoietic system
[1, 18]. T cells have been implicated as key players in the
maintenance of psoriasis and the pathogenesis appears to
involve a cytokine network centered on IL-17/IL-23 and
TNF𝛼 [19–22].
Here we provide evidence that members of the interleu-
kin-1 receptor family are differentially expressed in psoriatic
and healthy peripheral blood T cells. While the proportions
of regulatory,memory, na¨ıve, and na¨ıve regulatory T cell pop-
ulations within the CD4+ T cell pool are similar in psoriatic
and healthy individuals in the peripheral blood; differences
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Figure 4: Soluble IL-1R2 protein secretion is not significantly
different in healthy and psoriatic Treg andTeff cells. Cell populations
were separated by magnetic bead and flow cytometer mediated cell
sorting method as described. Supernatants of control and activated
regulatory (Treg) and effector (Teff) T cells were harvested after
three days. Experiments were performed with three parallel samples
from each condition following the manufacturer’s protocol. Slightly
higher levels of sIL-1R2 in supernatants of psoriatic T cells were
detected compared to healthy samples; however, no significant
difference was observed.
in the expression of the IL-1 receptors, becoming prominent
especially upon activation, may contribute to the pathogene-
sis of psoriasis. Here we also provide additional information
on effector/regulatory T cell characteristics by showing that
there are fundamental differences between the expression of
the signal transmitting and decoy IL-1 receptors on Treg and
Teff cells.
Interleukin-1 is one of the cytokines linking innate and
adaptive immune responses, and it has long been implicated
in the pathogenesis of psoriasis [10, 23], with recent findings
further supporting this notion [24]. IL-1𝛼 activity within
psoriatic lesions has been shown to be reduced, relative to
both normal epidermal levels [23] and nonlesional skin [10,
24]. On the other hand, increased IL-1𝛽 production has been
reported in psoriatic lesional skin [24]. A highly inducible
IL-1R2 receptor expression was observed in epidermal cells,
being overexpressed in psoriatic lesions relative to healthy
control biopsies [25]. More recently, increased serum levels
of the IL-1 receptor antagonist were detected in patients with
psoriasis compared to matched controls [26]. Expression of
several novel members of the IL-1 family (IL-1F6, IL-1F8, IL-
1F9, and IL-1F5) was increased 2 to 3 orders of magnitude in
psoriasis plaque versus uninvolved psoriatic skin, inducing
the expression of antimicrobial peptides and matrix met-
alloproteinases in epidermal cells [27]. Chemical irritation
of murine skin overexpressing the IL-1 family member IL-
1F6 leads to an inflammatory condition similar to human
psoriasis [28]. Clearly, from these studies, the significant role
formembers of the IL-1 family in psoriasis can be established.
Differential expression of several ligands and receptors of the
IL-1 family have extensively been investigated in psoriasis;
however, the possible interaction of immune cells with cells
of the epidermis via these cytokines/cytokine receptors has
not yet been looked at.
IL-1𝛼 and IL-1𝛽 both bind and activate the same receptor
[29], stimulating the release of several other proinflammatory
cytokines, such as TNF𝛼 and IL-6, and inducing a Th17 bias
in the cellular adaptive responses [13]. Both TNF𝛼 and the
IL-23/Th17 axis are strongly implicated in the pathogenesis
of psoriasis [30, 31], while IL-6 has recently been shown to be
important in preventing immune suppression by regulatory T
cells [14].Thus, several lines of evidence indicate that IL-1may
directly and indirectly contribute to inflammatory processes
in psoriasis.
Apart from the signal transmitting receptor (IL-1R1), IL-
1𝛼 and IL-1𝛽 can bind to several other members of the IL-1
receptor family. IL-1 receptors have recently been detected on
in vitro expanded human Treg cells [32]. IL-1R1 is a signalling
receptor for IL-1, while IL-1R2 neutralises IL-1 either as a
surface decoy receptor or as a cleaved and secreted receptor
isoform [9]. IL-1R1 is continuously expressed on resting Treg
cells, whereas upon activation it is upregulated on other T
cell subpopulations as well, while maintaining preferential
expression on the Treg subset [15]. Our results are in con-
cordance with recent findings about Tregs neutralising IL-
1𝛽 activity; thus it is likely that preferential expression of IL-
1R2 by these cells may possibly contribute to their suppressive
functions.
5. Conclusions
In our study, T cells stimulated through the TCR displayed
IL-1R1 expression profiles similar to previously published
results; that is, although Treg cells maintain the highest levels,
all CD4+ T cell subsets upregulate their IL-1R1 expression.
Interestingly, while under resting conditions the difference
between IL-1R1 expressing healthy and psoriatic T cells is
minimal, it becomes significantly higher in activated psoriatic
cells compared to activated healthy controls. In light of recent
data that IL-1𝛽, in combinationwith IL-2, can convert natural
human Treg cells intoTh17 lineage cells [33], it is tempting to
speculate that psoriatic T cells in an IL-1-rich environment,
such as the inflamed skin, may be more likely to transform
to effector cells than Treg cells of nonpsoriatic individuals.
Collectively, our findings suggest that the differential expres-
sion of IL-1 receptors on psoriatic T cells may contribute to
psoriasis development.
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